ESTRADIOL VALERATE - Generic Drug Details

What are the generic drug sources for estradiol valerate and what is the scope of patent protection?

Estradiol valerate is the generic ingredient in four branded drugs marketed by Ph Health, Am Regent, Dr Reddys, Fosun Pharma, Hikma, Watson Labs, Xiromed, and Savage Labs, and is included in eleven NDAs. Additional information is available in the individual branded drug profile pages.

There are seven drug master file entries for estradiol valerate. Four suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for ESTRADIOL VALERATE

US Patents:	0
Tradenames:	4
Applicants:	8
NDAs:	11
Drug Master File Entries:	7
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	72
Patent Applications:	4,827
Drug Prices:	Drug price trends for ESTRADIOL VALERATE
What excipients (inactive ingredients) are in ESTRADIOL VALERATE?	ESTRADIOL VALERATE excipients list
DailyMed Link:	ESTRADIOL VALERATE at DailyMed

See drug prices for ESTRADIOL VALERATE

Recent Clinical Trials for ESTRADIOL VALERATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Universiti Kebangsaan Malaysia Medical Centre	PHASE2
Malihe Mahmoudinia	NA
Chulalongkorn University	NA

See all ESTRADIOL VALERATE clinical trials

Generic filers with tentative approvals for ESTRADIOL VALERATE

Applicant	Application No.	Strength	Dosage Form
		3MG;2MG;3MG	TABLET;ORAL
		1MG;2MG;2MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for ESTRADIOL VALERATE

Drug Class	Estrogen
Mechanism of Action	Estrogen Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for ESTRADIOL VALERATE

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for ESTRADIOL VALERATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys	ESTRADIOL VALERATE	estradiol valerate	INJECTABLE;INJECTION	083547-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Ph Health	DELESTROGEN	estradiol valerate	INJECTABLE;INJECTION	009402-004	Approved Prior to Jan 1, 1982	AO	RX	Yes	Yes
Fosun Pharma	ESTRADIOL VALERATE	estradiol valerate	INJECTABLE;INJECTION	040628-002	Oct 4, 2007		DISCN	No	No
Ph Health	DELESTROGEN	estradiol valerate	INJECTABLE;INJECTION	009402-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Hikma	ESTRADIOL VALERATE	estradiol valerate	INJECTABLE;INJECTION	203723-003	Apr 21, 2020	AO	RX	No	No
Hikma	ESTRADIOL VALERATE	estradiol valerate	INJECTABLE;INJECTION	203723-002	Apr 21, 2020	AO	RX	No	No

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Estradiol Valerate

Last updated: July 27, 2025

---

Introduction

Estradiol Valerate, a synthetic estrogen widely used in hormone therapy, contraception, and menopausal treatment, commands a significant role within the pharmaceutical landscape. As a licensed hormone replacement therapy (HRT), it is primarily formulated for managing menopausal symptoms, delivering hormone balance, and treating estrogen-responsive conditions. The evolving market environment, driven by demographic shifts, healthcare policies, and emerging therapeutic applications, imposes pivotal implications on its commercial trajectory.

---

Market Dynamics

Growing Demand Driven by Demographic Trends

The global aging population substantially boosts the demand for estrogen-based therapies. Women aged 50 and above, experiencing menopause, increasingly seek hormone replacement options such as Estradiol Valerate to alleviate vasomotor symptoms, osteoporosis risk, and urogenital atrophy. According to United Nations projections, the demographic proportion of women aged 50+ is anticipated to rise by nearly 20% over the next decade, directly translating into expanded market size for estrogen therapies [1].

Simultaneously, rising awareness around menopausal health and improved healthcare access in emerging economies propel market growth. Countries like China, India, and Brazil are witnessing increased adoption of hormone therapy as part of broader women’s health initiatives.

Regulatory Landscape and Patent Considerations

The regulatory rigor across territories influences Estradiol Valerate’s market dynamics. Generic formulations have gained prominence following patent expirations, notably around the early 2010s. Regulatory agencies such as the FDA and EMA enforce strict standards for bioequivalence, impacting the entry of generics and biosimilars. With patent cliff events, generic manufacturers can significantly reduce product prices, intensifying competition but also expanding accessibility.

New formulations and delivery systems, such as patches, gels, and implants, are subject to distinct regulatory pathways. These innovations, if approved, could extend product lifecycle and market share.

Therapeutic Innovation and Competitive Landscape

While Estradiol Valerate remains a mainstay in hormone therapy, competition stems from various fronts:

• Alternative estrogens and selective estrogen receptor modulators (SERMs), e.g., Raloxifene and Bazedoxifene, offering differing safety profiles.
• Non-estrogenic treatments addressing menopausal symptoms, including SSRIs and other neuromodulators.
• Bioidentical hormone products presenting perceived natural alternatives, though regulatory and clinical evidence vary.

Innovation continues with transdermal systems and subcutaneous implants, promising improved compliance and fewer systemic side effects, thereby influencing sales and market positioning.

Impact of Market and Technological Trends

Emerging trends—in particular, personalized medicine—drive tailored hormone therapies. Pharmacogenomics may enable optimized dosing and reduced adverse effects, potentially reshaping the competitive landscape.

Furthermore, increased focus on hormone therapy safety, especially concerning breast cancer risk and cardiovascular outcomes, compels manufacturers to develop formulations with improved risk profiles, which may influence R&D pipelines and regulatory approvals.

---

Financial Trajectory

Market Size and Revenue Forecasts

The global hormone therapy market, incorporating Estradiol Valerate, is projected to reach approximately USD 9.2 billion by 2027, growing at a CAGR of around 6-8% during 2023–2027 [2]. Within this, estrogen therapies constitute a substantial segment, benefitting from demographic trends and expanding indications.

Regionally, North America dominates due to high healthcare expenditure and widespread acceptance of hormone therapies. Asia-Pacific is the fastest-growing segment, driven by demographic shifts and increasing healthcare infrastructure development.

Pricing and Cost Dynamics

Post-patent expiration, generic Estradiol Valerate formulations have significantly reduced pricing, increasing market penetration but compressing profit margins for manufacturers. Innovative delivery platforms, such as transdermal patches, command premium pricing, supporting higher margins for differentiated products.

Manufacturing costs are influenced by stringent quality standards, sourcing of raw materials, and regulatory compliance. Continuous process improvements and scale economies are critical to maintaining profitability.

Investment and R&D Outlook

Investment in research aimed at reducing adverse effects and expanding indications enhances Estradiol Valerate’s long-term value. R&D efforts focus on alternative delivery systems, combination therapies, and bioequivalent formulations to sustain competitive advantage.

Major pharmaceutical companies are also exploring biosimilar and biobetter versions, potentially entering lucrative segments with high-volume sales, especially in emerging markets.

---

Challenges and Opportunities

Challenges:

• Safety concerns such as increased risk of breast cancer, thromboembolism, and cardiovascular events limit broader adoption.
• Regulatory hurdles for new formulations or indications can delay market entry.
• Ethical debates and public perception issues regarding hormone therapy influence prescribing patterns.

Opportunities:

• Development of safer, targeted formulations leveraging nanotechnology and novel excipients.
• Expansion into new therapeutic areas, such as transgender health or osteoporosis.
• Strategic collaborations and licensing, particularly in emerging markets, to boost access and sales volume.

---

Conclusion

The market for Estradiol Valerate presents a complex interplay of demographic reality, technological advancement, regulatory frameworks, and competitive forces. While patent expirations and generic proliferation challenge margins, innovation in delivery systems and expanding indications foster growth. The long-term financial trajectory hinges on continued R&D investments, safety profile improvements, and strategic geographic expansion.

---

Key Takeaways

• Aging populations, especially women over 50, significantly drive demand for Estradiol Valerate, with regional differences favoring North America and Asia-Pacific.
• Regulatory pathways and patent expirations shape market entry, pricing, and competition, affecting revenue streams.
• Innovation in formulations and delivery systems offers avenues for differentiation and premium pricing.
• Safety concerns influence prescriber preferences and market acceptance; addressing these through advanced formulations remains a priority.
• Strategic growth opportunities lie in emerging markets, personalized medicine, and expanding indications beyond traditional uses.

---

FAQs

1. What factors predominantly influence the pricing of Estradiol Valerate formulations?
Pricing is driven by patent status, manufacturing costs, formulation complexity, and regulatory approvals. Generic versions reduce prices post-patent expiration, while premium delivery systems command higher prices.

2. How do safety concerns impact the market for Estradiol Valerate?
Safety issues such as increased cancer risk and thromboembolic events discourage widespread use, leading to demand for safer formulations and limiting broad-market adoption.

3. What are the prospects of biosimilars and biobetters in the Estradiol Valerate market?
Biosimilars and biobetters are emerging as key competitors, especially in markets with high demand and patent expirations, offering potential for cost reduction and improved safety profiles.

4. Which emerging markets are expected to exhibit the highest growth for Estradiol-based therapies?
Asia-Pacific, driven by rising healthcare infrastructure and demographic shifts, alongside Latin America and parts of the Middle East, are poised for rapid growth.

5. How does the ongoing research impact the future of Estradiol Valerate?
Innovations targeting safety, delivery, and personalized treatments extend the therapeutic relevance and market longevity of Estradiol Valerate, fostering competitive advantage.

---

References

[1] United Nations Department of Economic and Social Affairs. World Population Ageing 2020.
[2] MarketsandMarkets. Hormone Therapy Market by Product, Application, and Region — Forecast to 2027.